Heart Transplant Rejection Therapeutic and Drug Pipeline Review H2
Global Heart Transplant Rejection Drugs and Companies Pipeline Review H2 2017PUNE, INDIA, January 11, 2017 /EINPresswire.com/ -- GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/867073-heart-transplant-rejection-pipeline-review-h2-2016
Heart Transplant Rejection - Pipeline Review, H2 2016
Heart transplantation is the therapy used in various heart diseases. Heart transplant replaces an injured or diseased heart with a healthy one. Risk factors associated with transplantation are bleeding, infection, clots, and cardiovascular disorders. Following a transplant, the immune system may consider the transplanted heart as foreign and may work against it. Patients may hence develop complications and eventually reject the new organ. Immunosuppressive drugs are administered simultaneously which prevent the body from either identifying or attacking the foreign organ via various immune responses thus blocking organ rejection and facilitating a successful transplant.
Pharmaceutical and Healthcare latest pipeline guide Heart Transplant Rejection – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Heart Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Heart Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Heart Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical stages are 5 respectively.
Heart Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Heart Transplant Rejection (Immunology).
- The pipeline guide reviews pipeline therapeutics for Heart Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Heart Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Heart Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Heart Transplant Rejection (Immunology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Heart Transplant Rejection (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Heart Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Heart Transplant Rejection Overview 5
Therapeutics Development 6
Pipeline Products for Heart Transplant Rejection - Overview 6
Pipeline Products for Heart Transplant Rejection - Comparative Analysis 7
Heart Transplant Rejection - Therapeutics under Development by Companies 8
Heart Transplant Rejection - Pipeline Products Glance 9
Early Stage Products 9
Heart Transplant Rejection - Products under Development by Companies 10
Heart Transplant Rejection - Companies Involved in Therapeutics Development 11
Astellas Pharma Inc 11
Nekonal Sarl 12
Noxxon Pharma AG 13
Pelican Therapeutics Inc 14
Heart Transplant Rejection - Therapeutics Assessment 15
Assessment by Monotherapy Products 15
Assessment by Target 16
Assessment by Mechanism of Action 18
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 23
AS-2521780 - Drug Profile 23
Product Description 23
ACCESS REPORT @ https://www.wiseguyreports.com/reports/867073-heart-transplant-rejection-pipeline-review-h2-2016
Get in touch:
+1 646 845 9349 / +44 208 133 9349
email us here